Clinical Trial Update: Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating the combination of ibrutinib and venetoclax in relapsed or refractory follicular lymphoma has completed enrollment with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Venclexta (venetoclax)

Snippet

Sponsor: Georgetown University | Conditions: Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-05-21